Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AICPA, Albumin, AU, begun, CLIA, GAAP, microalbuminuria, nongovernmental, SEC, vesting, visit, waiver
Removed:
exercise, nationwide, preliminary, recently, renew, treasury
Filing tables
Filing exhibits
Related press release
DGX similar filings
Filing view
External links
Exhibit 10.7
CONFIDENTIAL
Amendment #3 to the
Letter of Agreement between
SmithKline Beecham Corporation and
Quest Diagnostics Incorporated
1. | The purpose of this Amendment #3 to the Letter of Agreement effective January 1, 2008 between SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Quest Diagnostics Incorporated (hereinafter the “LOA”) is to extend the term referenced in section 2 of the LOA to the earlier of (i) July 31, 2008, or (ii) the full execution of a new comprehensive Global Clinical Trials Agreement. |
2. | All other terms and conditions of the LOA shall remain in full force and effect. |
3. | The parties hereto agree to this Amendment #3 to the LOA by their authorized signatures below. |
SMITHKLINE BEECHAM CORPORATION | QUEST DIAGNOSTICS INCORPORATED | ||
/s/ Paula M. Russella | /s/ Daniel P. Megronigle | ||
Paula M. Russella | Daniel P. Megronigle | ||
Sourcing Group Manager | Executive Director, Sales & Marketing | ||
June 26, 2008 | 25 June 2008 | ||
Date | Date |